Citi analyst Joanne Wuensch reiterated a buy rating for Johnson & Johnson stock (NYSE: JNJ) with a price target of $285. According to TipRanks, Wuensch has a 3-star rating with a success rate of 50.83% in price predictions. The analyst covers the healthcare sector extensively and recently provided forecasts for leading medical giants Boston Scientific, Edwards Lifesciences, and Medtronic. His estimates on JNJ bring fresh enthusiasm into the sector, which has mostly stagnated in value in 2026.

If the Citi analysts’ price prediction on Johnson & Johnson stock turns out to be accurate, an investment of $1,000 could turn into $1,270. That’s an uptick and return on investment (ROI) of approximately 27% from its current price of $225. It would also be considered stellar returns, as not every asset in the market delivers double-digit gains. According to his forecast, JNJ is among the handpicked games that are capable of making investors’ portfolios swell with profits.

Also Read: AI Trouble For Microsoft Stock: Banking Firm Cuts Price Target (MSFT)

Why Does Citi Predict Johnson & Johnson Stock Will Reach $285?

Citi analyst’s bullish price prediction comes after the pharma giant received approval from the US Food and Drug Administration (FDA) for the Caplyta drug. The FDA approved the drug after evaluating its safety and efficacy for the prevention of relapse in schizophrenia. The approval comes after a long-term data evaluation by the department and has given it a nod for production. Around 2.8 million adults in the US suffer from schizophrenia, and nearly 40% of the patients do not receive adequate care. The approval made Citi analyst give Johnson & Johnson stock a $285 price target.

In addition, the medical company has two more drugs in the pipeline that could receive an FDA nod. If that happens, Johnson & Johnson stock could rise further in value well into 2027. Therefore, an investment in JNJ now could be beneficial for the long term as the equity is trading at a discount. Even CNBC’s Mad Money host, Jim Cramer, has given JNJ a buy call in a recent segment, saying that this low price will not be for sale forever, and urged traders to buy the dips and accumulate the medical giant.